Anti–PD-1 in Combination With Trametinib Suppresses Tumor Growth and Improves Survival of Intrahepatic Cholangiocarcinoma in Mice

BACKGROUND & AIMS: Intrahepatic cholangiocarcinoma (iCCA) accounts for a fraction of primary liver cancers but has a 5-year survival rate of only 10%. Immune checkpoint inhibitors are effective in treating many solid cancers, but immune checkpoint inhibitor monotherapy has no clear benefit in iC...

Descripción completa

Detalles Bibliográficos
Autores principales: Wabitsch, Simon, Tandon, Mayank, Ruf, Benjamin, Zhang, Qianfei, McCallen, Justin D., McVey, John C., Ma, Chi, Green, Benjamin L., Diggs, Laurence P., Heinrich, Bernd, Greten, Tim F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8413239/
https://www.ncbi.nlm.nih.gov/pubmed/34033968
http://dx.doi.org/10.1016/j.jcmgh.2021.05.011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8413239/
https://www.ncbi.nlm.nih.gov/pubmed/34033968
http://dx.doi.org/10.1016/j.jcmgh.2021.05.011

Ejemplares similares